Muse Bio is a Boulder-based biotechnology company focused on advancing genome engineering through its ForgeCraft™ platform. ForgeCraft integrates computer-aided forward-design software, a proprietary benchtop biofoundry, and custom reagents, enabling researchers and production scientists to iterate on genetic constructs quickly and at high throughput. By streamlining design, build, and test cycles, the company aims to accelerate discovery and industrial applications across synthetic biology. With the new capital, Muse Bio plans to expand access to ForgeCraft for scientists worldwide and further develop the platform’s capabilities. Kevin Ness serves as the company’s CEO. The business has attracted a syndicate of top-tier life-science investors and, following its Series B, has secured at least $23 million in venture funding to date.

Total raised

$23M

Funding rounds

1

Latest round

Series B

Latest activity

Feb 2017